US medical device company Nevro has secured CE mark approval for its Senza Omnia spinal cord stimulation system (Senza Omnia SCS system) for delivering its HF10 therapy for the treatment of chronic pain.
The Omnia system is a new spinal cord stimulation (SCS) platform, which is said to consist of many new components like the new Omnia programmer that will enable physicians to easily provide a range of waveforms across the full SCS frequency spectrum, either separately or paired along with HF10.
Nevro said that it has also redesigned the patient remote to enhance programming capacity, thereby giving the flexibility to expand on the HF10 algorithm to enable physicians to provide extra waveforms.
The Senza Omnia spinal cord stimulation system also consists of a redesigned, slimmer patient charger with an enhanced user interface. Nevro said that it has also given the SCS system with an updated and upgradeable implantable pulse generator.
The battery of the Omnia SCS system is said to be designed to work for more than ten years irrespective of the stimulation profile used. The system can be upgraded to accommodate future waveforms and frequencies owing to its full-body MRI approval.
According to Nevro, the Senza Omnia spinal cord stimulation system generates the widest range of frequencies between 2Hz and 10,000Hz compared to other SCS systems on the market.
D. Keith Grossman – Chairman, CEO and President of Nevro said: “This next-generation SCS system has been developed in close consultation with customers and is designed to provide a comprehensive solution to manage chronic pain.
“Omnia’s versatility means that patients now have access to a full range of SCS solutions and physicians can have the peace of mind that when they implant the system, they will have the capabilities needed to achieve the best possible outcomes for their patients.”